In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. He focuses on why, despite the positive trends, Dendreon is far from out of the woods. Watch and find out why investors who bid up shares as much as 30% intraday on Friday may be missing the bigger picture.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.